In a welcome move, Immunome Inc saw its Relative Strength Rating rise from 63 to 71 on Monday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Immunome Inc can continue to show renewed price strength and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Immunome Inc is now considered extended and out of buy range after clearing a 16.87 buy point in a first-stage cup without handle. See if the stock forms a new chart pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Immunome Inc posted -64% EPS growth last quarter. Sales rose 0%.
Immunome Inc earns the No. 270 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical and Dynavax Technologies are also among the group's highest-rated stocks.
